34 results
6-K
EX-99
RLFTF
Relief Therapeutics Holding AG
7 Oct 24
Relief Therapeutics Reports Positive Results from RLF-OD032 Proof-of-Concept Clinical Study for Phenylketonuria
4:35pm
for designing the next stages of our development and regulatory strategy. These results significantly increase the likelihood of meeting regulatory
6-K
EX-99
0b7lk
3 Apr 24
Invitation to the Extraordinary Shareholders' Meeting of RELIEF THERAPEUTICS Holding SA
4:31pm
6-K
EX-99
0rwwy 1e57x
27 Mar 24
Form 6-K Report of Foreign Private Issuer for March, 2024
4:15pm
6-K
EX-99
d5a vvfs7yfq
5 Dec 23
Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth
4:30pm
6-K
EX-99.2
lq914bd qckpglvf7hx1
15 Sep 23
Current report (foreign)
5:02pm
6-K
EX-99.3
0u1xwh auq4qkxdo
15 Sep 23
Current report (foreign)
5:02pm
20-F
EX-3.1
fdr xqird5
12 May 23
Annual report (foreign)
4:16pm
20-F
8iax0xvjzw2a4bcp
12 May 23
Annual report (foreign)
4:16pm
20-F
EX-10.2
fqlgfe18tf
12 May 23
Annual report (foreign)
4:16pm
6-K
EX-99
xkohr
4 Apr 23
Proposes a reverse stock split of its ordinary shares in preparation for planned listing to the Nasdaq Stock Market
5:20pm
F-1/A
e18gj5j
23 Dec 22
Registration statement (foreign) (amended)
1:35pm
F-1/A
pf0 y4ir1k22gczu34p
15 Nov 22
Registration statement (foreign) (amended)
4:31pm
6-K
EX-99
vqhp80onwd
14 Oct 22
Form 6-K Report of Foreign Private Issuer for October, 2022
4:30pm
6-K
EX-99
wl929
14 Oct 22
Form 6-K Report of Foreign Private Issuer for October, 2022
4:30pm
6-K
EX-99.3
os4ue x1zt1nw0aad
15 Sep 22
2022 to Date Highlights and Key Milestones
4:30pm
6-K
EX-99.1
fod6e kvcl7z4ifupt3a
15 Sep 22
2022 to Date Highlights and Key Milestones
4:30pm